Spero Therapeutics (SPRO) Non-Current Assets (2016 - 2026)
Spero Therapeutics' (SPRO) quarterly Non-Current Assets came in at $1.4 million in Q1 2026, down 52.95% YoY from $3.0 million in Q1 2025, and down 13.72% on a QoQ basis from $1.6 million in Q4 2025.
Spero Therapeutics (SPRO) Non-Current Assets (2016 - 2026) Analysis & Trends
Spero Therapeutics (SPRO) has 11 years of Non-Current Assets data on file, last reported at $1.4 million in Q1 2026.
- Quarterly Non-Current Assets fell 52.95% year-over-year to $1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.6 million (down 79.7% YoY) and the FY2025 annual result came in at $1.6 million, down 50.02% from the prior year.
- Non-Current Assets retreated to $1.4 million in Q1 2026, from $1.6 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $51.2 million in Q4 2023 to a low of $1.4 million in Q1 2026.
- A 5-year average of $11.6 million and a median of $10.5 million in 2023 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2023 — Non-Current Assets soared 355.68% — and 2024, when it tumbled 93.62%.
- Tracing SPRO's Non-Current Assets over 5 years: stood at $11.2 million in 2022, then surged by 355.68% to $51.2 million in 2023, then plunged by 93.62% to $3.3 million in 2024, then sank by 50.02% to $1.6 million in 2025, then retreated by 13.72% to $1.4 million in 2026.
- The last three Non-Current Assets figures came in at $1.4 million (Q1 2026), $1.6 million (Q4 2025), and $1.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 468.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 18.06 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 6.80 Bn |
| 10 | Spero Therapeutics | 70.14 Mn | 19.37 Mn | - | 1.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.18 Mn |
| Mar 31, 2026 | 1.41 Mn |
| Dec 31, 2025 | 1.63 Mn |
| Sep 30, 2025 | 1.85 Mn |
| Jun 30, 2025 | 2.72 Mn |
| Mar 31, 2025 | 3.00 Mn |
| Dec 31, 2024 | 3.27 Mn |
| Sep 30, 2024 | 3.53 Mn |
| Jun 30, 2024 | 27.66 Mn |
| Mar 31, 2024 | 27.55 Mn |
| Dec 31, 2023 | 51.18 Mn |
| Sep 30, 2023 | 4.88 Mn |
| Jun 30, 2023 | 10.54 Mn |
| Mar 31, 2023 | 10.88 Mn |
| Dec 31, 2022 | 11.23 Mn |
| Sep 30, 2022 | 11.59 Mn |
| Jun 30, 2022 | 11.67 Mn |
| Mar 31, 2022 | 13.13 Mn |
| Dec 31, 2021 | 13.20 Mn |
| Sep 30, 2021 | 12.92 Mn |